Robert Spiera is a Rheumatology/Immunology physician affiliated with Hospital for Special Surgery. OpenAlex indexes 301 publications with 17,096 citations (h-index 62); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1088 Park Avenue
New York, NY 101281132
Telephone
212-860-2100Provider last certified this registry record 26 Apr 2021.
Clinical trials
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Sponsor: Robert Spiera, MD
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Sponsor: Hospital for Special Surgery, New York
- Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Sponsor: Corbus Pharmaceuticals Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20252 payments
- Boehringer Ingelheim International GmbHProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
41.8%Folate Analog Metabolic Inhibitor16.6%Methotrexate95%Rasuvo5%Part D<11 patientsTNF inhibitor13.8%Enbrel Sureclick46%Humira(Cf) Pen37%Enbrel17%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
16%Corticosteroid8.1%Prednisone100%Part D≥27 patientsAntidiarrheal microorganisms5.2%Folic Acid100%Part D<11 patients+ 2 more classes in this area
Antiparasitic
14%Antimalarial14%Hydroxychloroquine Sulfate100%Part D≥54 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper
New England Journal of Medicine
2023 - Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
Kidney International Reports
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lockshin, MD
Hospital for Special Surgery
Lionel Ivashkiv, MD
Hospital for Special Surgery
Vivian Bykerk, VIVIAN, BYKERK, MD
Hospital for Special Surgery
Jane Salmon, MD
Hospital for Special Surgery
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”